[{"id":"996d882f-fae7-40b0-9fb5-12daec76b9ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT04607200","created_at":"2021-01-19T20:31:41.807Z","updated_at":"2024-07-02T16:36:18.687Z","phase":"Phase 2","brief_title":"AGEN2034 \u0026 AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma","source_id_and_acronym":"NCT04607200","lead_sponsor":"Agenus Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • zalifrelimab (UGN-301)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 09/13/2021","primary_completion_date":" 09/13/2021","study_txt":" Completion: 09/13/2021","study_completion_date":" 09/13/2021","last_update_posted":"2022-01-11"}]